Eli Lilly acquires inflammatory specialist Ventyx for $1.2bn
Eli Lilly has agreed to acquire autoimmune oral drug developer Ventyx Biosciences, representing the big pharma company’s latest push to …
Post
-
-
GSK to file for approval of twice-yearly hep B drug on positive Phase III data
GSK’s six-monthly triple-action investigational antisense oligonucleotide (ASO) candidate has demonstrated a clinically and statistically significant functional cure in chronic hepatitis …
-
Octapharma receives FDA approval for new Fibryga formulation in AFD
Octapharma has received approval from the US Food and Drug Administration (FDA) for a new 2-gram (g) formulation of Fibryga …
-
Day One concludes Mersana Therapeutics acquisition
Day One Biopharmaceuticals has concluded its acquisition of Mersana Therapeutics after meeting all the tender offer conditions. The tender offer expired …
-
Amgen buys Dark Blue Therapeutics in $840m oncology deal
Amgen has agreed to acquire UK-based biotech Dark Blue Therapeutics for up to $840m, making it the first pharma takeover …
-
Amgen buys Dark Blue Therapeutics in $840m oncology deal
Amgen has agreed to acquire UK-based biotech Dark Blue Therapeutics for up to $840m, making it the first pharma takeover …
-
Eli Lilly signs $1.3bn obesity-focused research deal with Nimbus
Eli Lilly has signed a research and licence agreement with Nimbus Therapeutics, aiming to develop a new oral weight loss …
-
Cellenkos gains FDA orphan drug status for CK0804 to treat myelofibrosis
Cellenkos has received orphan drug designation from the US Food and Drug Administration (FDA) for its investigational CK0804 regulatory T …
-
Zai Lab’s Augtyro receives NMPA approval for solid tumours in China
Zai Lab has received approval from China’s National Medical Products Administration (NMPA) for the supplemental new drug application (sNDA) for …
-
CDC shrinks childhood vaccine recommendation list to mirror “peer nations”
The US Centers for Disease Control (CDC) has shifted its stance on childhood vaccination, having minimised its routine recommendation list …
-
Takeda and Protagonist seek FDA approval for rusfertide to treat PV
Takeda and Protagonist Therapeutics have jointly submitted a new drug application (NDA) seeking approval from the US Food and Drug …
-
Aktis Oncology kicks 2026 IPO cycle off with $210m target
The IPO class of 2026 is likely to receive its first incumbent, after Aktis Oncology set its sights on a …
-
Podcast: Healthcare’s biggest 2025 trends and 2026 predictions
As the healthcare industry embarks on a new year, there are several factors that look set to impact pharmaceutical and …
-
Arrowhead receives Health Canada authorisation for Redemplo to treat FCS
Arrowhead Pharmaceuticals has received authorisation from Health Canada for its small interfering RNA (siRNA) medicine, Redemplo (plozasiran), as an adjunct …
-
Sanofi and Earendil Labs forge $2.56bn autoimmune deal
Ahead of JP Morgan 2026, pharmaceutical giant Sanofi has inked another deal with Helixon Therapeutics-affiliated startup Earendil Labs, which will …
